

# Exploring patient characteristics and treatment in real-world endometrial cancer patients users of platinum therapy

Gabriela Abreu, PhD<sup>1</sup>; Juliana Queiroz, MSc<sup>1</sup>; Thiago Luiz Nogueira da Silva, PhD<sup>1</sup>; Claudia Soares, MD, PhD<sup>1</sup>; Patricia Menezes, MBA<sup>1</sup>; Mariano Carrizo, MD<sup>2</sup>; Paula Scibona, MD<sup>3</sup>; Ventura A Simonovich, MD<sup>3</sup>; Maria C Riggi, MD<sup>3</sup>; Florencia Cravero, MD<sup>3</sup>; Laura Jotimlansky, MD<sup>2</sup>

<sup>1</sup>GSK, Rio de Janeiro, Brazil; <sup>2</sup>GSK, Buenos Aires, Argentina; <sup>3</sup>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina



ECHOS-A highlights that PBT (mainly carboplatin-paclitaxel) is a well-established 1L treatment option for patients with EC in Argentina, including during early stages of the disease

RWD88  
Digital poster



SCAN ME


## Aim

To describe clinical characteristics of patients with endometrial cancer (EC) who received first-line (1L) platinum-based therapy (PBT) in Argentina



## Study Design

Endometrial Cancer Health Outcomes Study in Argentina (ECHOS-A)



- Retrospective cohort study using anonymized medical records of privately insured patients at Hospital Italiano de Buenos Aires
- Analysis of patients receiving 1L PBT


\*Surgery, radiotherapy, or systemic therapy (chemotherapy, hormone therapy, or immunotherapy).

## Background


- EC is the **sixth most common cancer** among women worldwide<sup>1</sup>
- There are **limited** real-world data demonstrating the clinical characteristics of patients with EC, particularly in South America<sup>2,3</sup>
- Understanding patients' clinical characteristics in this context is a **valuable approach** for highlighting unmet medical needs and **improving patient care**

## Results


Patients with EC diagnosis




1L systemic therapy\*



1L PBT



1L carboplatin-paclitaxel



Among patients receiving 1L PBT (n=146)

Demographics

**Age**  
years, mean (SD)  
65.4 (10.4)

**BMI**  
≥25 kg/m<sup>2</sup>  
80%




**Follow-up**  
months, mean (SD)  
35.8 (28.5)

Time from index to 1L therapy, months

**6.1 (10.8)**  
Mean (SD)

**3.2 (2.2)**  
Median (IQR)

FIGO staging<sup>†</sup>



Duration of 1L therapy, mean (SD)

**4.1 (4.2)** months  
Stage I/II

**3.5 (2.5)** months  
Stage III/IV

\*Chemotherapy, hormone therapy, or immunotherapy; <sup>†</sup>123 patients (16%) were missing FIGO staging data.

## Abbreviations

1L, first line; BMI, body mass index; EC, endometrial cancer; ECHOS-A, Endometrial Cancer Health Outcomes Study; FIGO, International Federation of Gynecology and Obstetrics; IQR, Interquartile range; PBT, platinum-based therapy; SD, standard deviation.

## References

- World Cancer Research Fund International. <https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/> (accessed March 18, 2024);
- Bruggmann D et al. *J Transl Med* 2020;18:386;
- Paulino E and de Melo AC. *Rev Bras Ginecol Obstet* 2023;45:e401–e408.

## Acknowledgements

Medical writing support was provided by Pallavi Patel, PhD, of Luna, OPEN Health Communications, and was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines ([www.ismpp.org/gpp-2022](http://www.ismpp.org/gpp-2022)).

## Disclosures

This study was funded by GSK (study ID: 221709). The authors declare the following real or perceived conflicts of interest during the past 3 years in relation to this presentation: GA, JQ, and TLNS are complementary employees of GSK and do not hold stocks or shares. CS, PM, MC, and LJ are employees of and hold stocks in GSK. MCR reports receiving speaker fees from AstraZeneca and GSK. PS, VAS, and FC have no conflicts of interest to declare.